BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:00 PM
 | 
Oct 04, 2012
 |  BC Extra  |  Clinical News

Ablynx gains on Phase II RA data

Ablynx N.V. (Euronext:ABLX) gained EUR 0.94 (18%) to EUR 5.78 on Thursday after reporting interim Phase II data of IV ALX-0061 to treat moderate to severe active rheumatoid arthritis (RA). In 34 evaluable patients on a stable background of methotrexate, 3 mg/kg doses...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >